Response to Alemtuzumab for Leukemic Cutaneous T-Cell LymphomaResponse to Alemtuzumab for Leukemic Cutaneous T-Cell Lymphoma

Patients with leukemic cutaneous T-cell lymphoma (CTCL) who have diffuse erythema are more likely to experience complete response to alemtuzumab therapy, according to results from a small series. Reuters Health Information
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Hematology-Oncology News Source Type: news

Related Links:

CONCLUSIONS: Our results show that STAT3 is activated in advanced cases and associated with large-cell transformation, while the activation of NFAT and NFκB is maintained throughout the disease. These findings could have important diagnostic and therapeutic implications. This article is protected by copyright. All rights reserved. PMID: 31049933 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
In conclusion, we believe that the data presented in this research add new relevant information for a better definition of the pathological states associated with HTLV-1 infection, particularly in relation to the distinct subcellular expression of HBZ in the different pathological contests and related pathologies. Whether HBZ cytoplasmic and nuclear localization in the natural history of HTLV-1 infection represents a marker of infection or is part of the mechanism governing the evolution toward HAM/TSP or ATL is the challenge for future investigation. Author Contributions GF, MB, and RA conceived the work. GF, MB, and AT...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Conclusion: CCL21 induced mTOR activation in MyLa cells, followed by expression of MALAT1, causing cell migration. MALAT1 and mTOR are potential therapeutic targets for MF.
Source: In Vivo - Category: Research Authors: Tags: Experimental Studies Source Type: research
In this study we assessed the use of multiple immune checkpoint inhibitors on the proliferation and Th1 cytokine production of CD4 and CD8 T-cells of patients with L-CTCL.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Translational Studies Source Type: research
Conclusions Epidemiological studies have repeatedly helped identify definitive triggers for several diseases. As highlighted in this perspective report, previous studies strongly argue for the interplay between intrinsic factors and putative preventable extrinsic triggers/promoters for CTCL. Given the evidence of geographical regional clustering of CTCL patients, CTCL occurrence in unrelated family members and recent evidence implicating S. aureus in the pathogenesis/progression of CTCL, more research is needed to decipher the precise mechanism by which specific environmental exposures may be driving the pathogenesis of t...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions The major challenges in the development of adoptive cell therapy for T cell tumors, as mentioned above, remain fratricide, T cell aplasia and the potential for leukemic transduction or poor T cell function if used in the autologous setting. Approaches to overcome fratricide include the genetic modification and deletion of the T cell antigen in the case of long-term CAR-T cell persistence or regulated CAR-T expression. To ensure restoration of T cell immunity, transient CAR expression can be achieved incorporation of a CAR suicide gene, transient CAR expression using mRNA electroporation, or short-lived NK cell...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Discussion In this section, we discuss the mechanisms responsible for lymphomagenesis in the various inborn errors of immunity and provide an overview of the treatment. Defects in Immune Responses That Predispose to Lymphomagenesis in PIDDs The complex immune mechanisms and their interplay that predisposes to neoplastic transformation of B or T cells and development of lymphomas in PIDD patients has not been fully elucidated. However, it is expected that the etiology in most cases is multifactorial and related to a dynamic regulation of immune response and environmental triggers (Figure 3). An underlying intrinsic susce...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Abstract Cutaneous-type adult T-cell leukemia-lymphoma is treated with antiviral or skin-directed therapy. Medications that are used to treat skin lesions of cutaneous T-cell lymphomas are also used for the cutaneous-type adult T-cell leukemia-lymphoma. Etretinate, a synthetic retinoid, has been used for treating cutaneous T-cell lymphomas; however, its clinical effectiveness for the treatment of cutaneous-type adult T-cell leukemia-lymphoma has not been fully studied. We conducted a retrospective assessment of the efficacy and safety of etretinate in 9 patients with cutaneous-type adult T-cell leukemia-lymphoma. ...
Source: Acta Dermato-Venereologica - Category: Dermatology Authors: Tags: Acta Derm Venereol Source Type: research
In conclusion, MPT0G413 and BTZ synergistically inhibit MM viability, providing a framework for the clinical evaluation of combined therapies for MM. Introduction Multiple myeloma (MM) is a B cell malignancy characterized by the proliferation of bone marrow (BM) plasma cells and the production of large amounts of abnormal immunoglobulins (1) In the United States, it was estimated that 30,770 new MM cases would be diagnosed in 2018, accounting for 1.8% of newly diagnosed cancer cases (2). Furthermore, 12,770 MM-related deaths in 2018 accounted for an estimated 2.1% of all cancer deaths (2). In the past decade, MM t...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study investigates RAD23B and STAT3 gene perturbations in a large cohort of primary Sézary cells and the effect of FK228 treatment on tyrosine phosphorylation of STAT3 (pYSTAT3) and RAD23B expression. We report RAD23B copy number variation in 10% (12/119; p ≤ 0.01) of S S patients, associated with reduced mRNA expression (p = 0.04).
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
More News: Cancer & Oncology | Cutaneous T cell lymphoma | Dermatology | Health | Hematology | Leukemia | Lymphoma | Skin | T-cell Lymphoma